New drug cocktail aims to wipe out myeloma cells in newly diagnosed patients

NCT ID NCT06997081

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether combining elranatamab (an immune-boosting drug) with lenalidomide and dexamethasone can eliminate all traces of multiple myeloma in newly diagnosed patients. About 104 participants will receive the drugs in cycles over several months. The main goal is to see if the cancer becomes undetectable in bone marrow after 12 cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elranatamab, lenalidomide, and dexamethasone
What this could lead to: If successful, this combination could help more newly diagnosed myeloma patients achieve deep remission with no detectable cancer cells.
What could go wrong: This is an early Phase 2 study with only 104 participants. The treatment may cause side effects like immune reactions or infections, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

University of Miami
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.